The anti-tumor effects of human immunodeficiency virus protease inhibitors: Ready for real time?

International Journal of Cancer

Volumn 128, Issue 1, 2011, Pages 1-2

  Stebbing, Justin ^a   Bower, Mark ^a  

^a NONE

Author keywords

Cancer; HIV; Kaposi sarcoma; Matrix metalloproteinases; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; BASIC FIBROBLAST GROWTH FACTOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; MATRIX METALLOPROTEINASE; PACLITAXEL; PROTEASOME; SAQUINAVIR; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL ACTIVITY; CELLULAR IMMUNITY; CHORIOALLANTOIS; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; EDITORIAL; GRAFT REJECTION; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; VIRUS INFECTION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; INDINAVIR; MATRIX METALLOPROTEINASE 2; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SAQUINAVIR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78349236873     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25590     Document Type: Editorial

References (18)

1. International Collaboration on HIV and Cancer: Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults. J Natl Cancer Inst 2000; 92: 1823 30.
2. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B,. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. Aids 2003; 17: F17 22.
3. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B,. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. Aids. 1999; 13: 2105 11.
4. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O, Calvo F,. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12: F45 F49.
5. Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, Sarmati L, Farchi F, Tisone G, Piazza A, Pisani F, Angelico M, Leone P, Citterio F, Ensoli B, Rezza G,. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. J Infect. 2001; 43: 195 9.
6. Emond JP, Marcelin AG, Dorent R, Milliancourt C, Dupin N, Frances C, Agut H, Gandjbakhch I, Calvez V,. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol. 2002; 40: 2217 9.
7. Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M,. Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma. J Clin Oncol 2007; 25: 2230 5.
8. Stebbing J, Gazzard B, Bower M,. The host control of lytic and latent infection with human herpesvirus-8. J Infect Dis 2006; 193: 1051 3.
9. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, Wills M, Lehner PJ,. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A 2008; 105: 1656 61.
10. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J,. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23: 5224 8.
11. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F,. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990; 345: 84 6.
12. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B,. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002; 8: 225 32.
13. Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S, Mandalia S, Gotch F, Gazzard BG, Bower M,. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann Oncol 2003; 14: 1660 6.
14. Murdaca G, Campelli A, Setti M, Indiveri F, Puppo F,. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. Aids. 2002; 16: 304 5.
15. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M,. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53 68.
16. Langford A, Ruf B, Kunze R, Pohle HD, Reichart P,. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol. 1989; 120: 709 13.
17. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE,. Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res 2009; 11 Suppl 3: S15
18. Stebbing J, Bower M,. What can oncologists learn from HIV? Lancet Oncol 2003; 4: 438 45.